(Q54696645)

3 June 2018

title

Real-time PCR quantification of c-erbB-2 gene is an alternative for FISH in the clinical management of breast carcinoma patients. (English)

1 reference

3 June 2018

1 reference

6

Jahn M Nesland

1 reference

3 June 2018

Elin Faye Borgen

4

object named as

Elin Borgen

1 reference

3 June 2018

Assia Bassarova

5

object named as

Assia Bassarova

1 reference

3 June 2018

author name string

Zhenhe Suo

1

1 reference

3 June 2018

Kathinka U Daehli

2

1 reference

3 June 2018

Christian Fr Lindboe

3

1 reference

3 June 2018

publication date

1 October 2004

1 reference

3 June 2018

International Journal of Surgical Pathology

published in

1 reference

3 June 2018

volume

12

1 reference

3 June 2018

issue

4

1 reference

3 June 2018

page(s)

311-318

1 reference

3 June 2018

Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line

cites work

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

Signal transduction by receptors with tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

Protein tyrosine kinase structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

Type 1 protein tyrosine kinases in breast carcinoma: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

The clinical evaluation of HER-2 status: which test to use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

c-erbB-2 oncoprotein expression in primary and advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

The long term prognostic significance of c-erbB-2 in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

First-line Herceptin monotherapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

Current status of HER2 testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

Current perspectives on HER2 testing: a review of national testing guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

Evaluation of HER2/neu status by real-time quantitative PCR in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

What can we learn from Herceptin trials in metastatic breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

The development and clinical use of trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

Recommendations for HER2 testing in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

Evaluation of non-formalin tissue fixation for molecular profiling studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106689690401200404

10.1177/106689690401200404

21 January 2018

Identifiers

DOI

1 reference

3 June 2018

PubMed ID

15494857

1 reference

3 June 2018